Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UVAX-Lassa vaccine
- Development stage
- Preclinical
- Lead developer
- Uvax Bio
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
UVAX-Lassa is a preclinical vaccine candidate developed by Uvax Bio for the prevention of Lassa Fever. It utilizes the proprietary 1c-SApNP® (one-component self-assembling protein nanoparticle) platform, which is designed to display Lassa virus glycoprotein (GPC) trimers in their native-like prefusion conformation on the surface of a single nanoparticle. This multivalent presentation mimics the repetitive structure of the virus, potentially leading to enhanced B-cell activation and a more potent neutralizing antibody response compared to traditional protein subunit vaccines. The 1c-SApNP technology aims to provide a stable, highly immunogenic, and easily manufacturable vaccine solution for Lassa virus, a significant cause of viral hemorrhagic fever in West Africa.
- Other names
- Lassa Fever nanoparticle vaccineUvax Lassa vaccine
02
Targets
GPC (Lassa virus glycoprotein complex)
Beyond the preview
Go deeper on UVAX-Lassa vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UVAX-Lassa vaccine.